Hepatocellular Carcinoma

BARCELONA, Spain — Nivolumab did not significantly extend OS compared with sorafenib as first-line therapy for patients with advanced hepatocellular carcinoma, according to results of the randomized phase 3 CheckMate 459 trial presented at European Society for Medical Oncology Congress.

Treatment with Cabometyx as second-line therapy for patients with advanced hepatocellular carcinoma who previously received Nexavar demonstrated superior progression-free survival and improved overall survival compared with Stivarga, according to a study presented at the International Liver Cancer Association 2019 meeting and a press release.

Nanobiotix announced positive results of the NBTXR3 activated by stereotactic body radiation, or SBRT, for the treatment of hepatocellular carcinoma and liver metastasis, according to a press release.

Tiziana Life Sciences provided additional positive data from the ongoing phase 2a clinical trial of milciclib for patients with unresectable or metastatic hepatocellular carcinoma and resistance or intolerance to Nexavar.

Researchers discovered that an elevated fatty liver index was an independent risk factor for all-cause mortality in patients coinfected with hepatitis C and HIV, regardless of liver fibrosis or sustained virologic response to hepatitis therapy.

The Laboratory for Advanced Medicine announced via a press release that the FDA granted breakthrough device designation to its liquid biopsy liver cancer detection test.

Recent studies have shown significant differences in patient survival and complications after liver transplantation with either a living donor or deceased donor organ. Additionally, awareness about living donor transplantation and the safety records for donors remains low among both physicians and the public.

Patients with hepatocellular carcinoma on a liver transplantation waitlist who had public insurance had worse waitlist outcomes compared with those who had Kaiser Permanente or other private insurance, according to data published in JAMA Network Open.

Increasing physician experience in the management of Nexavar-related adverse events has led to longer treatment duration and improved overall survival rates in patients with hepatocellular carcinoma, according to results from a nearly 10-year retrospective study.

The top stories in hematology/oncology last week both resulted from FDA actions: Allergan’s agreeing to the agency’s request to recall specific models of its breast implants that may be related to a rare type of lymphoma and the agency granting breakthrough therapy designation to the Keytruda-Lenvima combination for hepatocellular carcinoma.